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Acute viral bronchiolitis is one of the most common medical emergency situations in infancy, and physicians caring
for acutely ill children will regularly be faced with this condition. In this article we present a summary of the
epidemiology, pathophysiology and diagnosis, and focus on guidelines for the treatment of bronchiolitis in infants.
The cornerstones of the management of viral bronchiolitis are the administration of oxygen and appropriate fluid
therapy, and overall a “minimal handling approach” is recommended. Inhaled adrenaline is commonly used in
some countries, but the evidences are sparse. Recently, inhalation with hypertonic saline has been suggested as an
optional treatment. When medical treatment fails to stabilize the infants, non-invasive and invasive ventilation may
be necessary to prevent and support respiratory failure. It is important that relevant treatment algorithms exist,
applicable to all levels of the treatment chain and reflecting local considerations and circumstances.
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Bronchiolitis is an acute lower respiratory tract infection
in early childhood caused by different viruses, with cough-
ing, wheeze and poor nutrition as the major symptoms
[1-3]. A substantial proportion of children will experience
at least one episode with bronchiolitis, and as much as 2-
3% of all children will be hospitalized with bronchiolitis
during their first year of life [1-4]. Bronchiolitis is the most
common reason for hospitalization of children in many
countries, challenging both economy, area and staffing in
paediatric departments. Respiratory syncytial virus (RSV)
is the most common virus causing bronchiolitis, occurring
in epidemics during winter months [1,2].
Some infants, particularly those with risk factors, will
have a severe course of bronchiolitis. Bronchiolitis is the
most common medical reason for admission of children
to intensive care units (ICU), providing challenges re-
garding ventilation, fluid balance and general support
[5]. This may be a particular challenge for ICUs without
a specialised paediatric section.
The aim of this article is to review current knowledge
of severe bronchiolitis in infancy, with emphasis on the
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We performed a non-systematic search in PubMed up to
January 2014, with the following words in different combi-
nations; bronchiolitis, infants, children, severe, epidemi-
ology, pathophysiology, guidelines, treatment, management,
oxygen, hypertonic, saline, adrenaline, steroids, fluid, nutri-
tion, continuous positive airway pressure (CPAP), bi-level
positive airway pressure (BiPAP), high flow nasal cannulae
and ventilation. Included studies and papers were not
systematically evaluated regarding design and quality. How-
ever, we have emphasised recent guidelines, Cochrane re-
views and other expert reviews.Clinical definition
There is no uniform definition of bronchiolitis, and no
definite age limitation. In 2006, a subcommittee of the
American Academy of Pediatrics (AAP) together with the
European Respiratory Society (ERS) underlined that bron-
chiolitis is a clinical diagnosis, recognized as “a constella-
tion of clinical symptoms and signs including a viral upper
respiratory prodrome followed by increased respiratory ef-
fort and wheezing in children less than 2 years of age” [3].
In Europe, wheezing is regarded as a less important
finding [2,6,7]. During recent years, several studies from
Europe and the USA have included children only up to
12 months of age [2,8,9]. Children hospitalized for wheez-
ing between 12 and 24 months of age may have a higher
risk for having asthma, and with different pathophysiologyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mainly focus on data from studies in infants with bron-
chiolitis younger than 12 months of age.
Epidemiology
Approximately 20% of children develop bronchiolitis
during their first year of life, and studies from the USA
have found increasing rates of bronchiolitis (188/1000
infants in 1996/97 to 265/1000 in 2002/03) in this age
group [6,12]. In a Norwegian study, the mean annual
hospitalization incidence for RSV bronchiolitis was 21.7
per 1000 for children below 12 months [13], and in a
large study from England the admission rate for all in-
fants with bronchiolitis below 12 months of age was 24.2
per 1000 [14].
Bronchiolitis is generally seasonal, appearing most fre-
quently in epidemics during the winter months [15]. For
RSV, the same seasonal pattern is observed throughout
the world, with most cases occurring from October until
May on the northern hemisphere [15,16]. Adults with
chronic obstructive lung disease and other immunocom-
promised patients may have RSV infection throughout
the year and represent a reservoir of the virus [17,18].
Bronchiolitis is a disease with high morbidity, but low
mortality. Death from respiratory failure in bronchiolitis
is rare and range for RSV bronchiolitis from 2.9 (UK) to
5.3 (USA) deaths per 100 000 children below 12 months
[19,20]. Differences may be caused by diagnostic proce-
dures as well by socioeconomic conditions. A study from
the UK underlines that the mortality rate for bronchio-
litis in children below 12 months is low and falling, from
21.5 to 1.8 per 100 000 children (age 1 to 12 months)
from 1979 to 2000, reflecting improvements in paediat-
ric intensive care [21].
Pathophysiology
RSV is the most common virus involved in children with
bronchiolitis. In most studies it accounts for 60–80% of
the bronchiolitis cases in children below 12 months of
age [1,11,22-24]. In children below 12 months of age,
Rhinovirus (RV) is the second most common virus (14–
30%), thereafter human bocavirus (14–15%), human
metapneumovirus (3-12%), entero-, adeno-, corona and
influenza viruses (1–8%). Dual infections are reported in
20–30% of children, but does not seem to be associated
with increased severity [6,11,22,25].
The infection starts in the upper respiratory tract,
spreading to the lower airways within few days. The in-
flammation in the bronchioles is characterized by a peri-
bronchial infiltration of white blood cell types, mostly
mononuclear cells, and oedema of the submucosa and
adventitia [2,6]. Damage may occur by a direct viral in-
jury to the respiratory airway epithelium, or indirectly by
activating immune responses [6].Oedema, mucus secretion, and damage of airway epithe-
lium with necrosis may cause partial or total airflow ob-
struction, distal air trapping, atelectasis and a ventilation
perfusion mismatch leading to hypoxemia and increased
work of breathing [1,2]. Smooth-muscle constriction
seems to play a minor role in the pathologic process of
bronchiolitis [2].
Clinical characteristics
Bronchiolitis often starts with rhinorrhoea and fever,
thereafter gradually increasing with signs of a lower re-
spiratory tract infection including tachypnoea, wheezing
and cough. Very young children, particularly those with a
history of prematurity, may appear with apnoea as their
major symptom [2,6]. Feeding problems are common.
On clinical examination, the major finding in the youn-
gest children may be fine inspiratory crackles on ausculta-
tion, whereas high-pitched expiratory wheeze may be
prominent in older children [2]. By observation, the in-
fants may have increased respiratory rate, chest move-
ments, prolonged expiration, recessions, use of accessory
muscles, cyanosis and decreased general condition.
No formal scoring system for the severity of bronchio-
litis exists, but a suggestion for the grading into mild,
moderate and severe bronchiolitis based on guidelines
from New Zealand and Scotland is given in Table 1 [7,26].
In a study including children with bronchiolitis from an
out-patient clinic, the resolution of symptoms took more
than 14 days in 40% of the children, and approximately
10% had symptoms after 4 weeks [6]. The median length
of hospitalization in a large study including children below
12 months was only one day (IQR 0–3) [14], and in a Nor-
wegian study the mean length of hospitalization was
80 hours (SD 67) [23].
Risk factors for bronchiolitis are male gender, a history
of prematurity, young age, being born in relation to the
RSV season, pre-existing disease such as bronchopul-
monary dysplasia, underlying chronic lung disease,
neuromuscular disease, congenital heart disease, exposure
to environmental tobacco smoke, high parity, young
maternal age, short duration/no breastfeeding, maternal
asthma and poor socioeconomic factors. However, the
majority of children hospitalized for bronchiolitis have no
underlying condition [6,12,14].The same conditions may
also be risk factors for a more severe course. Recently,
specific gene polymorphisms have been associated with a
risk for more severe bronchiolitis [27].
Assessment
Clinical assessment
The diagnosis of bronchiolitis is made clinically, as de-
scribed [3]. Risk factors for a severe course should be
recognised, including young age which is associated with
increased risk of apnoea, prolonged hospitalization,
Table 1 Assessment of the severity of bronchiolitis in infants < 12 months*
Mild bronchiolitis Moderate bronchiolitis Severe bronchiolitis**
Feeding Normal Less than usual Not interested
>half the normal < half the normal
Respiratory rate < 2 months > 60/min >60/min >70/min
> 2 months > 50/min
Chest wall recessions Mild Moderate Severe
Nasal flare or grunting Absent Absent Present
Sp02 >92% 88-92% <88%
General behaviour Normal Irritable Lethargic
*Modified from New Zealand guidelines and SIGN guidelines [7,26].
**Not all criteria need to be met to categorize as severe bronchiolitis.
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anical ventilation [2,3].
Pulse oxymetry should be included in the clinical as-
sessment of bronchiolitis when possible, as it can detect
hypoxemia not suspected by the clinical examination
(Table 1) [2,3].
The course of bronchiolitis is variable, and repeated
assessments should be performed, especially in infants
with risk factors.
Laboratory assessment
Except for pulse oxymetry, no routine diagnostic tests
have been shown to have a substantial impact on the
clinical course of bronchiolitis, and recent guidelines
and evidence-based reviews recommend that no diag-
nostic tests are used routinely [2,3,5,6,28]. Implementa-
tion of guidelines for the assessment and treatment of
infants with bronchiolitis has reduced the use of diag-
nostic as well as therapeutic options, with a further re-
duction in costs and length of stay [2,29-33].
The clinical course and management of bronchiolitis
are similar and not influenced by identification of the
viral agent [2,3]. However, identifying a viral etiology is
shown to reduce the use of antibiotics, the number of
investigations and the length of stay [6,30]. Dependent
on the setting, a viral diagnosis may be warranted for
cohorting of patients and may reduce nosocomial infec-
tions, which may have impact on the long-term progno-
sis of the child [3]. However, this has been questioned by
others [34].
Examination by chest X-ray may increase the rate of
antibiotic prescription without improving any outcome,
and may in less than 1% reveal lobar consolidations sug-
gesting the need of antibiotics [5,35]. An X-ray may,
however, be more likely to add positively in children
with high and prolonged fever, oxygen saturation < 90%,
chronic cardiopulmonary disease and in children in need
of admission to an ICU or mechanical ventilation [5,36].
Blood tests are commonly taken in children with bron-
chiolitis, but are not of clinical value in most patientsand not recommended routinely [2,3,37]. Tests to be in-
cluded may be total blood count and C-reactive protein
if a secondary bacterial infection is suspected, and elec-
trolytes in infants with feeding problems and signs of de-
hydration. Blood gases is warranted and useful in infants
with severe respiratory distress and potential respiratory
failure [6].
Management
General management
Management of acute bronchiolitis is generally support-
ive, as no medical treatment has shown to improve im-
portant clinical outcomes, such as length of hospital
stay, use of supportive care or transfer to an intensive
care unit. A conservative, “minimal handling” approach
seems beneficial, especially for the youngest age group
(<3 months) [1,2,23]. A prone position may improve
oxygenation and is suggested for infants if they are care-
fully observed [1,38]. Careful nasal suctioning may be
beneficial in infants with copious secretion [1,39].
Oxygen
Oxygen should be administered in hypoxic infants with
bronchiolitis, and administered via nasal cannulae or a
face mask [1]. However, there is no consensus on what
level of oxygen saturation (SpO2) oxygen support should
be aiming at, and no randomized controlled trials have
compared alternative oxygen supplementation regimes
[1,40]. In the UK, oxygen is commonly given to achieve
a SpO2 of 92-95%, while the AAP recommends a limit of
SpO2 of 90% in otherwise healthy children [1-3,7,39].
Observational studies, however, indicate that a goal of
90%, as compared to 94%, has the potential to signifi-
cantly reduce length of hospital stay [41,42], and the
AAP guidelines recommend a reduced level of monitor-
ing as the infants improve [3].
Fluid and nutrition
Maintaining hydration is an important part of the care
of infants with bronchiolitis. The respiratory distress due
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feeding and eventually lead to poor hydration [1]. Fur-
ther, tachypnoe and fever increases fluid loss, potentially
worsening the dehydration [43,44]. Oral feeding may be
sustained in milder cases, if needed by small volume fre-
quent feed, and breastfeeding should be encouraged.
However, a substantial part of infants hospitalized for
bronchiolitis will be in need of fluid supplementation, ei-
ther as intravenous (IV) fluid or with enteral feeding by
gastric tube (GT) [1,2,44]. Traditionally, IV fluid has
been given in many countries, and is also recommended
in the present AAP guidelines [3]. The advantage of IV
fluids could be a decreased risk of aspiration and no
interference with breathing [45,46], but with the disad-
vantage of possibly creating a catabolic state due to low
calorie intake, and bearing a higher risk of fluid overload
and electrolyte imbalance [43,44,46]. Through GT feed-
ing, infants may achieve a better nutritional status and
nitrogen balance, which may be beneficial for recovery,
and may be a route for giving expressed breast milk
[44,47]. Feeding by GT may be given as boluses, or con-
tinuously in case of major respiratory distress [1].
Currently there is not sufficient evidence for or against
the use of GT feeding in infants with bronchiolitis [46],
and in a recent large study from Australia no differences
in major outcomes were found between the two
methods [48]. However, feeding by GT has been increas-
ingly adopted, and used as routine in some countries
[41,49,50], including the recent guidelines of the Norwe-
gian Paediatric society [51]. In a large Scottish study of
bronchiolitis, no children received IV fluids, and no
complications related to feeding by GT were reported
[41]. Recently, a minor randomized pilot study compar-
ing IV fluid and feeding of GT showed no difference re-
garding the duration of oxygen supplementation or
length of stay between the two methods [43].
Few studies have addressed the appropriate amount
of fluid to be given during replacement in bronchio-
litis. Guidelines recommend that infants should receive
enough fluid to restore fluid loss and avoid dehydra-
tion, and the amount should not exceed 100% of daily
fluid requirements, normally set to 100 ml/kg for
infants < 10 kg [3]. However, fluid retention due to
inappropriate secretion of antidiuretic hormone has
been reported in bronchiolitis, and clinicians should
be aware of the possibility of overhydration [1,52,53].
Consequently, 70-80% of the daily requirements may
be recommended, especially in those with severe disease
[1,3,44]. In these children, close monitoring of weight,
serum and urine-osmolality and serum electrolytes may
guide treatment [1]. Probably, possible overhydration
will be a less problem during enteral feeding, permit-
ting the body to absorb the needed amount of fluid and
electrolytes.Inhaled saline
Inhaled normal saline (0.9%) is commonly used for chil-
dren with bronchiolitis to increase clearing of mucous,
and is included as placebo in many studies evaluating
the effect of bronchodilators or hypertonic saline. How-
ever, we are not aware of any randomised study com-
paring normal saline with no treatment, and normal
saline is not suggested in current guidelines and re-
views [1-3,6,39]. Consequently, no recommendations
can be given.
Inhaled hypertonic saline has, in patients with various
diseases, shown to increase mucociliary clearance pos-
sibly through induction of an osmotic flow of water to
the mucus layer and by breaking ionic bonds within the
mucus gel [54]. Recent metaanalyses including more
than 1000 infants with mild to moderate bronchiolitis,
concluded that the use of hypertonic saline (3-5%) may
reduce the length of hospital stay and the rate of
hospitalization [55,56]. However, due to the possible side
effect of bronchospasm, all but few patients received a
combination with a bronchodilator. The optimal delivery
interval, concentration and delivery device remain un-
clear. The short term effect was conflicting, as four trials
showed no such effect [55]. In a recent study, 7% hyper-
tonic saline with epinephrine did not have any effect on
the clinical severity score [57].
A recommendation of hypertonic saline inhalations
based on the current evidence must include a broncho-
dilator. As recent evidence strongly supports the “min-
imal handling” approach to infants with bronchiolitis
[23], we do not support such a recommendation at this
time. Several trials with hypertonic saline without bron-
chodilators are ongoing, from which results may adjust
guidelines [1].
Inhalations with bronchodilators
In addition to bronchodilation, inhalation with adrenaline
may reduce mucosal swelling, which has led to frequent
use in infants with bronchiolitis. However, a clinically im-
portant, significant effect has been documented for nei-
ther adrenaline nor beta-2-agonists. Studies on short-term
effects show conflicting results. A recent Cochrane review
concludes that inhaled (racemic) adrenaline does not im-
prove important clinical outcomes such as length of hos-
pital stay or the use of supportive care in moderate to
severe bronchiolitis inpatients [58]. This is supported by a
recent large Norwegian randomised controlled trial (RCT)
of 404 infants [23]. In this study, treatment “as needed”
rather than on a fixed schedule resulted in less inhalations
(12 vs. 17 per day), shorter hospital stay (47.6 vs. 61.3 hours),
less use of supplemental oxygen (38.3 vs. 48.7%) and less
ventilatory support (4.0 vs. 10.8%). The effect was predom-
inantly seen in children <3 months (25 hours reduced hos-
pital stay), which also tended to have a negative effect of
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tive approach particularly in this age group. Adrenaline
is therefore not recommended as a standard treatment
in infants with bronchiolitis, but a trial might be per-
formed in children >3 months, with critical evaluation
of effect with respect to continuation of administration
[23]. Beta-2-agonists are not recommended for infants
with bronchiolitis [59,60].
Steroids
A recent metaanalysis including 17 RCTs concluded
that there is no beneficial effect of systemic corticoste-
roids in children with bronchiolitis, neither on rate of
hospitalization for outpatients nor on length of stay for
inpatients [61]. However, one study has shown a benefi-
cial effect of dexamethasone (0.15 mg/kg every 6 h for
48 h) in mechanically ventilated children, suggesting that
this may be an option in critically ill patients [62]. Fur-
ther, the combined therapy with inhaled epinephrine
and high-dose oral dexamethasone (1 mg/kg at presenta-
tion and 0.6 mg/kg for an additional 5 days) appeared to
reduce the rate of hospital admission in a small study
[63]. However, this treatment cannot be recommended
until evaluation in larger studies has been done.
Additional medication
Antibiotics is commonly used in children with lower re-
spiratory tract infections, but a Cochrane review including
543 infants concludes that there is no evidence for the use
of antibiotics in general [64]. However, antibiotics may
more frequently be warranted due to concurrent bacterial
infections in infants with severe disease, especially those
needing mechanical ventilation [65]. There is no role for
antiviral therapy in bronchiolitis [66].
Surfactant therapy has been suggested for critically ill
patients on mechanical ventilation. So far, this has been
evaluated in only three small studies, and a recent
Cochrane review concluded that there is insufficient
evidence for such treatment [67]. The use of recombin-
ant human deoxyribonuclease has not been efficacious
on any of the outcome variables in children with bron-
chiolitis [68].
Non-invasive and invasive ventilation
Continuous positive airway pressure (CPAP) with a nasal
tube or a nasal mask has been widely used in children
with moderate or severe bronchiolitis. CPAP may act by
recruiting collapsed airways and the corresponding al-
veoli, giving a reduction in mean airway resistance. This
further increases the emptying of the lungs during expir-
ation, resulting in a decreased hyperinflation and work
of breathing, and improved gas exchange [69,70].
Contrasting the widely use, the documentation for the
use of CPAP in bronchiolitis is sparse. A recent systematicreview concluded that the evidence supporting the use of
CPAP to reduce PCO2 and respiratory distress is of low
quality, and it has not been shown that the use of CPAP
reduces the need for invasive ventilation [69]. Only two
small RCTs have been performed [71,72], the other studies
have a before-after design [73-77]. However, these studies
have found that the use of CPAP in bronchiolitis is safe,
and on average reduces the capillary PCO2 from before to
shortly after CPAP is initiated with 0.8 to 1.3 kPa [69].
The pressure used during ventilation with CPAP is
commonly set to 4–8 cm H2O, and a pressure of 5 cm
H2O has been efficient in reducing PCO2. Recently, a
prospective study suggested that a nasal CPAP level of
7 cm H2O was most efficient in reducing respiratory dis-
tress and improving the breathing pattern [78].
Heliox is a mixture of helium and oxygen and a low-
density gas. It may have a beneficial role in bronchiolitis
by transforming turbulent into laminar gas flow and
thereby improving oxygenation and the washout of CO2
[79]. The combination of heliox and CPAP (CPAP-He)
has been evaluated in three studies. All the studies in-
cluded few children, one quasi RCT and two before-after
studies [69,80-82]. All three studies showed a significantly
decrease in transcutaneous or arterial PCO2 and respira-
tory distress. However, as no blinded RCT has been per-
formed, it must be concluded that more evidence is
needed before CPAP-He can be included in guidelines
[69]. Heliox therapy without the use of a tight CPAP or
combined with a nasal cannulae has been shown to be
ineffective [83].
Though no uniform criteria have been published, com-
mon criteria for which children should be treated with
CPAP are respiratory distress, high oxygen requirement
or increasing pCO2 and apnoeas [1]. In a recent study,
the strongest predictors for CPAP treatment were oxy-
gen requirement, low oxygen saturation, younger age
and higher respiratory rate [84].
The use of heated humidified high-flow nasal cannulae
(HFNC) has increasingly been introduced as an alternative
to nasal CPAP [85-91], also in a general paediatric ward
[92]. The method is currently used in neonatal medicine
[93], and may generally act by increasing the pharyngeal
pressure, leading to a reduction in respiratory efforts and
improving respiratory distress [94]. Based on the current
literature, a recent review concludes that HFNC may be
feasible in infants with bronchiolitis and may decrease the
need for intubation [87,90]. HFNC may be better tolerated
than nasal CPAP [86,89,95], and larger paediatric units
have replaced CPAP with HFNC as the first-line non-
ventilatory support in bronchiolitis [86]. However, no ran-
domized trial has yet evaluated the effect in bronchiolitis
patients, and the most recent study concludes that there is
insufficient evidence to determine the effectiveness of
HFNC in infants with bronchiolitis [96]. Serious air leak
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treated with HFNC [97].
The safety of HFNC and CPAP may be arguments for
the early introduction of non-ventilatory support in chil-
dren with moderate bronchiolitis [69]. However, mech-
anical ventilation may still be necessary in infants with
insufficient support by nasal CPAP or HFNC. Risk fac-
tors include prematurity, low birth weight and broncho-
pulmonary dysplasia, and further those with apnoe, low
oxygen saturation, poor oral intake and severe retrac-
tions on admission [98,99].
There is no consensus on which ventilator technique
is the best for children with bronchiolitis [70,100]. BothInitial assessment
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It is important to avoid nosocomial spread of RSV and
other respiratory viruses from children with bronchiolitis
[102]. RSV can survive up to seven hours on surfaces
and is transmitted directly or indirectly by touch [103].
Further, air sampling in subjects infected with RSV has
detected RSV RNA up to 700 cm from head of the pa-
tients bed [104]. Hand decontamination by antimicrobial
soap or alcohol based hand rubs before and after patient
contact, and also after removing gloves and after contact
with possible decontaminated objects, is an important
strategy for primary prevention [3]. However, wearing
masks has not been shown to have additional benefit [3].
Management plan
Based on the above considerations and recent guidelines,
we suggest a treatment plan for acute bronchiolitis in
children, including dose recommendations (Figure 1).
All institutions caring for children with bronchiolitis
should provide a clear in-house treatment algorithm to
their staff, taking local considerations and circumstances
into account.
Differential diagnostic considerations
In most cases, the diagnosis of bronchiolitis is clinically
evident and no further tests are indicated to rule out
other diagnosis [2]. However, other diagnosis may be
considered in a child with atypical presentations includ-
ing severe respiratory distress, and recurrent symptoms,
and in a child presenting with otherwise typical symp-
toms, but with no signs of a viral infection [2]. Differen-
tial diagnosis may include gastroesophageal reflux,
laryngotracheobroncholamacia, pertussis, foreign body
aspiration, vascular ring and other mediastinal obstruc-
tions or other congenital lung diseases [2,6]. Asthma
may be considered in the oldest infants with recurrent
episodes of wheeze, but the overlap with asthma is less
likely when bronchiolitis is only defined in infants youn-
ger than 12 months of age [6].
Outcome
Children hospitalized with bronchiolitis in infancy have
an increased risk of subsequent asthma, reduced lung
function and increased bronchial hyperresponsiveness
[24,105]. Except from in the studies by Sigurs et al. [8],
they do not seem to have an increased risk of atopy
[106]. The increased risk of asthma is particularly found
among children hospitalized with RSV negative bron-
chiolitis or bronchiolitis due to Rhinovirus [24,107],
whereas the association between RSV bronchiolitis in in-
fancy and subsequent respiratory morbidity decreases
with age [108]. The association between bronchiolitis
and later asthma is complex and probably related to viraletiology, genetic, structural, immunological, inflamma-
tory and environmental mechanisms [109].
Conclusion
Bronchiolitis is the most common reason for hospitalization
during infancy, being a burden for the child and family, and
bearing huge costs for the healthcare systems. The main
principles for treatment include minimal handling, main-
tenance of oxygen saturation, fluid balance and nutrition.
Other therapeutic options are inhalations with epinephrine,
normal saline or hypertonic saline, but the evidences for
their use are sparse. CPAP and heated humidified high-flow
nasal cannulae are commonly used in those with respiratory
failure, but more high-quality studies are needed to prove
their efficacy. Very few children may be in need of mechan-
ical ventilation.
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